APPROXIMATELY 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapsed/refractory forms of the disease (R/R DLBCL). With effective forms of treatment currently lacking, there is an increasing need for the development of novel therapies to successfully treat the disease. This review provides a summary of the research presented by a panel of three experts at the virtual webcast symposium conference hosted by PeerVoice on 20th May 2021.
EMJ Hematology 9 [Supplement 6] . 2021
November 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/07/Extensive-Left-Sided-Venous-Thrombi-and-Bilateral-Pulmonary-Emboli-in-the-Context_website-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/Hem-Interview-IMROZ-Study-web-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/04/Niamh-OConnell-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Pier-Mannucci-940x564.png)